<DOC>
	<DOCNO>NCT03000686</DOCNO>
	<brief_summary>This study conduct examine GSK2586881 , recombinant human ACE2 peptide , modulate acute hypoxic pulmonary vasoconstriction ( HPV ) response healthy volunteer . The study single-center , randomize , placebo-controlled double blind ( sponsor open ) . Subjects randomize receive single intravenous ( IV ) dose GSK2586881 placebo ( saline ) crossover design . The primary objective study evaluate effect single IV dose GSK2586881 HPV response healthy volunteer exercise hypoxic condition . Approximately 35 subject enrol maximum 56 day .</brief_summary>
	<brief_title>Study GSK2586881 Acute Hypoxia Exercise</brief_title>
	<detailed_description />
	<mesh_term>Anoxia</mesh_term>
	<criteria>Between 18 40 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator [ consultation Medical Monitor require ] agree document find unlikely introduce additional risk factor interfere study procedure . Note : Screened subject laboratory value outside normal range may repeat inclusion study discretion Investigator . Screening echocardiogram good quality , without clinically significant abnormality , mildmoderate tricuspid regurgitation sufficient reliable estimation PASP , determine echocardiography core laboratory responsible cardiologist . Screening PASP within normal range accord site standard . Subjects reside altitude &gt; 1500 meter ( ) 7 day last 4 month Able complete study procedure . Any contraindication ( orthopedic , cardiac etc . ) perform exercise bicycle ergometer . Body weight 50 100 kilogram ( kg ) ( inclusive ) . Male female ( non Child Bearing Potential ) : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication least five halflives study medication OR cycle spermatogenesis follow five terminal halflives last dose study medication . a. Vasectomy documentation azoospermia . b . Male condom plus partner use one contraceptive option ( Contraceptive subdermal implant , Intrauterine device intrauterine system , Oral Contraceptive either combine progestogen alone , Injectable progestogen , Contraceptive vaginal ring , Percutaneous contraceptive patch ) . This allinclusive list method meet follow GSK definition highly effective : failure rate le 1 % per year use consistently correctly , applicable , accordance product label . For nonproduct method ( e.g. , male sterility ) , investigator determines consistent correct use . The GSK definition base definition provide International Conference Harmonization ( ICH ) .The investigator responsible ensure subject understand properly use method contraception . A female subject eligible participate pregnant ( confirm negative urine human chorionic gonadotrophin [ hCG ] test ) , lactate , follow condition applies : Nonreproductive potential define , 1 . Premenopausal females one following ( Documented tubal ligation , Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , Hysterectomy , Documented Bilateral Oophorectomy ) . 2 . Postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) estradiol level consistent menopause ( refer laboratory reference range confirmatory level ) ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent describe study protocol include compliance requirement restriction list consent form study protocol . ALT &gt; 1.5x Upper limit normal ( ULN ) . Bilirubin &gt; 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QTc &gt; 450 millisecond ( msec . ) Unable refrain prescription nonprescription drug , include agent active central nervous system , vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication throughout study , unless opinion Investigator and/or GSK Medical Monitor ( need ) medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 240 milliliter [ ml ] ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . For potent immunosuppressive agent , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 ml within 56 day . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>GSK2586881 , Acute hypoxia , Exercise</keyword>
</DOC>